AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CYTK · NASDAQ · Biotechnology

Cytokinetics (CYTK)

Developer of muscle-directed medicines led by MYQORZO for hypertrophic cardiomyopathy.

$67.90

After hours+0.29 (+0.43%)

At close$67.61(+0.07%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	0	2	1	0	0	17	2	67	2	18	19	32
Cost of revenue	83	85	82	80	85	94	100	2	3	3	2	3
Gross profit	−82	−83	−81	−79	−84	−77	−98	64	−1	15	17	29
	40	44	46	51	57	62	57	176	166	193	201	205
Research & development	83	85	82	80	85	94	100	113	99	102	96	98
	40	44	46	51	57	62	57	66	69	92	105	104
General & administrative	40	44	46	51	57	62	57	66	69	92	105	104
Other expenses	−83	−85	−82	−80	−85	−94	−100	−2	−3	0	0	3
Operating income	−122	−127	−126	−130	−141	−139	−156	−112	−167	−178	−184	−176
	−7	−9	−9	−13	−20	−11	−6	−23	−139	−5	−22	−23
Interest income	7	8	8	12	17	15	14	13	10	11	11	14
Interest expense	14	17	17	24	22	23	23	24	26	30	33	35
Other non-operating income	−7	−8	−8	−11	−3	−12	−17	−1	113	5	−11	23
Income before tax	−129	−137	−136	−143	−161	−150	−161	−134	−306	−183	−206	−199
Net income from continuing operations	−129	−137	−136	−143	−161	−150	−161	−134	−306	−183	−206	−199
Net income	−129	−137	−136	−143	−161	−150	−161	−134	−306	−183	−206	−199
EPS, basic	−$1.35	−$1.38	−$1.33	−$1.31	−$1.36	−$1.27	−$1.36	−$1.12	−$2.55	−$1.49	−$1.67	−$1.50
EPS, diluted	−$1.35	−$1.38	−$1.33	−$1.31	−$1.36	−$1.27	−$1.36	−$1.12	−$2.55	−$1.50	−$1.67	−$1.50
Weighted average shares, basic	96	99	102	109	118	118	118	119	120	122	123	132
Weighted average shares, diluted	96	99	102	109	118	118	118	119	120	122	123	132
EBITDA	−114	−113	−116	−117	−136	−125	−136	−108	−277	−180	−169	−192
Depreciation & amortization	2	6	2	2	2	2	2	2	3	3	3	7
EBIT	−115	−120	−118	−119	−138	−127	−138	−110	−280	−183	−173	−199